News

21 Jun 2018

Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services

REPROCELL’s BioServe and Biopta tissue procurement networks combine to create a new service isolating human primary cells.
Read More >>

13 Jun 2018

REPROCELL's footprint extends to serve life sciences in India

REPROCELL India (formerly BioServe Biotechnologies) is a state-of-the-art biotechnology company with a mission to serve the life sciences research ecosystem.
Read More >>

25 May 2018

Do animal experiments translate to humans? A report by Elsevier and Bayer uses big data to shed new light on a hotly debated topic

At REPROCELL, we are continually striving to expand our range of human fresh tissue and 3D models of drug safety and efficacy. REPROCELL hosts the only catalogue of human fresh tissue assays with searchable categories of tissue type, receptor and endpoints across a range of therapeutic areas.
Read More >>

18 May 2018

Factors to consider when planning a iPSC reprogramming project

When you are considering beginning a project involving iPSC reprogramming, there are several factors to consider when choosing a reprogramming technology and a service provider.
Read More >>

1 2 3 4 >>

Visit REPROCELL at the “North East England Life Science Showcase” in Cambridge, MA (USA) on November 30, 2017

08/11/2017

For life scientists in the USA, the North East England Life Science Showcase will be held on Thursday, November 30th, 2017 at the Boston Mariott Hotel in Cambridge, MA.

 

View the program and sign up here.

 

The orgainzer of the North East England Life Science Showcase, Prof. Anne Dickinson, Director of Alcyomics, will be giving a showcase presentation titled In vitro pre-clinical testing for predicting adverse immune reactions. Alcyomics’ pre-clinical Skimune®3D service uses REPROCELL’s Alvetex in its non-artificial human skin explants for safety and efficacy assessment of novel compounds and drugs.

 

Also included in the event program is a showcase presentation by REPROCELL’s Senior Technical Product Manager, Robert Annand, PhD. Dr Annand’s presentation on Human Tissue and 3D-Cell based Models for Drug Discovery will showcase REPROCELL’s pre-clinical contract research organization provides unique custom pharmacology assay services using freshly-sourced human tissues and 3D tissue models.

 

REPROCELL Europe Ltd.’s operations are based in North East England and in nearby Scotland. Our CSO, Prof. Stefan Przyborski, is also Professor of Cell Technology at Durham University (in North East England). Our CEO, Dr David Bunton, an expert in vascular pharmacology, was co-founder of Biopta (now REPROCELL Europe’s Center for Predictive Drug Discovery in Glasgow, Scotland) which specializes in drug discovery contract research using ethically sourced live human tissue from a network of hospitals.

 

The event is free to attend. View the program and sign up here. Please register by Friday, November 17th.

Live chat by BoldChat